MedEnrich | Página principal
Continue Watching
últimos vidéos
últimos vidéos
Brightcove Home Latest Listing
Cáncer de mama
Cáncer de mama
Brightcove Cards Listing
Cáncer de próstata
Brightcove Cards Listing
Mieloma múltiple
Mieloma múltiple
Brightcove Cards Listing
Popular en MedEnrich
Popular in Sin nombre
Cancer de prostata7m 0s
Abiraterone in Metastatic Castration Sensitive Prostate Cancer
Two Clinical Trials with long term follow up (LATITIDUE 52 Months) & STAMEPDE (72 Months) have confirmed effectiveness of Abiraterone in mHSPC.
1
Abiraterone in Metastatic Castration Sensitive...
Mieloma múltiple4m 12s
Key Practice Points -Myeloma Related Renal Impairment
In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.
1
Key Practice Points -Myeloma Related Renal...
Myelodysplastic Syndromes31m 24s
Improving Diagnosis of MDS -Innovative Solutions
Modern Web -Based digital tools based on 10 routinely used clinical parameters and Gradient Based Model can help in non-invasive diagnosis of MDS.
1
Improving Diagnosis of MDS -Innovative Solutions
Oncology4m 9s
Cardio Oncology in Prostate Cancer
Major cardiovascular toxicities associated with the prostate cancer treatment include arrhythmias, atherosclerosis, myocardial Infarction, hypertension & cardiomyopathy. Toxicities vary with the type of agent used in Prostate Cancer Treatment.
1
Cardio Oncology in Prostate Cancer
Cáncer de mama8m 55s
Understanding HER-2 Low Breast Cancer Entity & Treatment Strategy
Tumors with a HER-2 immunohistochemistry (IHC) score of 1 + or 2 + and a negative molecular reflex test have been classified as HER2-low Breast Cancers.
1
Understanding HER-2 Low Breast Cancer Entity &...
Myelodysplastic Syndromes8m 45s
Current Challenges in MDS Diagnosis and Consequences
Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.
1
Current Challenges in MDS Diagnosis and Consequences
Mieloma múltiple7m 47s
Exploring Optimal Duration of Lenalidomide Maintenance after ASCT
Best evidence for Lenalidomide maintenance after ASCT came from Meta-analysis of 3 trials (McCarthy et al, JCO 207) confirmed significant OS benefit with Lenalidomide maintenance.
1
Exploring Optimal Duration of Lenalidomide...
Cáncer de mama3m 36s
Tumor Infiltrating Lymphocytes as Predictive Biomarker in Breast Cancer
Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.
1
Tumor Infiltrating Lymphocytes as Predictive...
Cáncer de mama11m 28s
ESR1 Mutation in Hormone Receptor Positive Advanced Breast Cancer
ESR1 mutation leads to ligand independent activation of estrogen receptor. ESR1 mutations were first described in 1997 & their role remain underestimated as initial research was focused on primary tumor wherein these mutations were absent.
1
ESR1 Mutation in Hormone Receptor Positive Advanced...
Myelodysplastic Syndromes17m 59s
Genomics of AML -Therapeutic and Prognostic Implications
~40% of AML patients have targetable mutations. Younger patients often have FLT3-ITD or FLT3- TKD mutation. Mutations IDH-1 , IDH-2 & t-53 mutations are more common in elderly patients.
1
Genomics of AML -Therapeutic and Prognostic...
Seminarios web anteriores
Seminarios web anteriores
Webinar Cards Listing
Artículos
Artículos
Medbytes Cards Listing
